Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 10

Rhea-AI Summary

Royalty Pharma (Nasdaq: RPRX) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 8:15 a.m. ET. The conference offers a platform for the company to showcase its position as the largest buyer of biopharmaceutical royalties.

The webcast will be available on Royalty Pharma's Events page and archived for at least thirty days. Established in 1996, the company collaborates to fund innovation and holds royalties on over 40 leading therapies.

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 40^th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8:15 a.m. ET.

The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 40 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Johnson & Johnson’s Tremfya, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and nine development-stage product candidates.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

FAQ

When is Royalty Pharma's presentation at the J.P. Morgan Healthcare Conference?

Royalty Pharma will present on January 10, 2022, at 8:15 a.m. ET.

Where can I watch the Royalty Pharma webcast?

The webcast can be accessed on Royalty Pharma's Events page and will be archived for at least thirty days.

What does Royalty Pharma specialize in?

Royalty Pharma specializes in buying biopharmaceutical royalties and funding innovation in the biopharmaceutical industry.

How many commercial products does Royalty Pharma's portfolio include?

Royalty Pharma's portfolio includes royalties on more than 40 commercial products.

What major therapies are included in Royalty Pharma's portfolio?

The portfolio includes therapies like Imbruvica, Tremfya, and Xtandi, among others.